Bibliographical note© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
Funding: Biotechnology and Biological Sciences Research Council (BBSRC; via grants BB/N007417/1, BB/P025927/1 and BB/P022685/1 to RMB) and the Innovative Medicines Joint Undertaking under Grant Agreement number 115583 to the ND4BB ENABLE Consortium to RMB. EC Membrane Protein Consortium (E-MeP, FP6 LSHG-CT-2004-504601), the European Drug Initiative for Channels and Transporters (EDICT, FP7 Health-F4-2007-201924 and BBBSRC grant BB/D524832/1 to RMB and PJFH. MVD’s PhD studentship was funded by BBSRC iCASE BB/H016244/1 with Glycoform Ltd. PJFH is grateful to the Leverhulme Trust for an Emeritus Research Fellowship (Grant number EM-2014-045). BBSRC (MPSI BBS/B/14418), the Wellcome Trust (JIF 062164/Z/00/Z) and the University of Leeds. ‘Initiative d'Excellence’ program from the French State (Grant ‘DYNAMO’, ANR-11-LABEX-0011-01). PhD fellowship funded by the French Ministry of Research and Education.
- Recombinant membrane proteins
- Expression plasmid vector